Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more
The 10-day RSI Indicator for DYN moved out of overbought territory on August 07, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where DYN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DYN broke above its upper Bollinger Band on August 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on July 16, 2025. You may want to consider a long position or call options on DYN as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DYN just turned positive on July 16, 2025. Looking at past instances where DYN's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
DYN moved above its 50-day moving average on August 06, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where DYN advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 222 cases where DYN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.779) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). DYN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (286.048).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DYN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ANVIX | 28.04 | 0.18 | +0.65% |
Virtus NFJ Large-Cap Value Fund Inst | |||
FBLEX | 14.29 | 0.09 | +0.63% |
Fidelity Series Stk Selec Lg Cp Val | |||
UIPMX | 33.47 | 0.21 | +0.63% |
Victory Precious Metals & Minerals Instl | |||
FFNIX | 13.78 | 0.02 | +0.15% |
Fidelity Advisor Asset Manager 40% I | |||
EAAAX | 16.22 | -0.04 | -0.25% |
Gabelli Entpr Mergers & Acquisitions AAA |
A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.
Ticker / NAME | Correlation To DYN | 1D Price Change % | ||
---|---|---|---|---|
DYN | 100% | N/A | ||
RNA - DYN | 58% Loosely correlated | -2.59% | ||
CRNX - DYN | 54% Loosely correlated | -3.69% | ||
XNCR - DYN | 53% Loosely correlated | -1.23% | ||
SYRE - DYN | 52% Loosely correlated | N/A | ||
IDYA - DYN | 50% Loosely correlated | +3.08% | ||
More |